Vir Biotechnology, Inc. — Director's Dealing 2020

Apr 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2020-04-17

Reporting Person: Pang Phillip (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-17	Common Stock	M	8000	$0.855	Acquired	15777	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-17	Employee Stock Option (Right to Buy)	$0.855	M	8000	Disposed	2027-03-09	Common Stock (8000)	Direct

Footnotes

F1: 1/4 of the 111,111 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. The aggregate number of shares subject to the stock option has been reduced by one share to 111,110 shares due to rounding in connection with a partial exercise of the stock option and a reverse stock split effected prior to the Issuer's initial public offering.